Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Ludwig Center at Harvard
- Bayer
- Genentech
- GlaxoSmithKline
- Eli Lilly Japan
- Society for Academic Continuing Medical Education
- Bayer Yakuhin
- Eli Lilly and Company
- Kissei
- Boehringer Ingelheim España
- Roche
- Sanofi
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Boehringer Ingelheim Japan
- Ono Pharmaceutical
- Nippon Kayaku
- Foundation Medicine
- Merck
- AstraZeneca España
- Novartis
- Takeda Pharmaceutical Company
- Novartis Pharma
- G1 Therapeutics
- Celgene
- Canadian Asian Studies Association
- AbbVie
- Daiichi-Sankyo
- F. Hoffmann-La Roche
- Eisai
- Kyowa Kirin
- Astellas Pharma
- PharmaMar
- Roche España
- European Medicines Agency
- Chugai Pharmaceutical
- Les Laboratories Pierre Fabre
- Amgen
- Bristol-Myers Squibb
- Janssen Pharmaceutica
- Merck Sharp and Dohme United Kingdom
- Exelixis
This publication has 18 references indexed in Scilit:
- Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsMolecular Cancer Therapeutics, 2016
- Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitorJournal of Medicinal Chemistry, 2016
- TRKing Down an Old Oncogene in a New Era of Targeted TherapyCancer Discovery, 2015
- Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2014
- Molecular Pathways: ROS1 Fusion Proteins in CancerClinical Cancer Research, 2013
- Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers.2013
- Assessing quality of life in patients with colorectal cancer: An update of the EORTC quality of life questionnaireEuropean Journal of Cancer, 2007
- Interpreting the significance of changes in health-related quality-of-life scores.Journal of Clinical Oncology, 1998
- The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trialsEuropean Journal of Cancer, 1994
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993